BeaucheminPCarruthersR. MS arising during Tocilizumab therapy for rheumatoid arthritis. Mult Scler2016; 22: 254–256.
2.
WhitlockJEidelmanBWhitlockJ. et al. Demyelinating disease and axonal peripheral neuropathy in a 68-year-old male treated with tocilizumab for rheumatoid arthritis. Muscle Nerve2015; 52(S2): S129.
3.
SatoHKobayashiDAbeA. et al. Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: A case report. BMC Res Notes2014; 7: 641.
4.
BurmesterGRFeistEKellnerH. et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: The first phase IIIb real-life study (TAMARA). Ann Rheum Dis2011; 70(5): 755–759.
5.
KleiterIGoldR. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics2016; 13(1): 70–83.
